Cargando…
Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol
INTRODUCTION: Prophylactic human papillomavirus (HPV) vaccines have been shown to be highly effective in protecting women against cervical infections, high-grade abnormalities and cancer caused by the targeted HPV types. However, the evidence for their effectiveness in women living with HIV (WLWH) i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422845/ https://www.ncbi.nlm.nih.gov/pubmed/36008069 http://dx.doi.org/10.1136/bmjopen-2022-061650 |
_version_ | 1784777901705527296 |
---|---|
author | Murenzi, Gad Shumbusho, Fabienne Hansen, Natasha Munyaneza, Athanase Gage, Julia C Muhoza, Benjamin Kanyabwisha, Faustin Pierz, Amanda Tuyisenge, Patrick Anastos, Kathryn Castle, Philip E |
author_facet | Murenzi, Gad Shumbusho, Fabienne Hansen, Natasha Munyaneza, Athanase Gage, Julia C Muhoza, Benjamin Kanyabwisha, Faustin Pierz, Amanda Tuyisenge, Patrick Anastos, Kathryn Castle, Philip E |
author_sort | Murenzi, Gad |
collection | PubMed |
description | INTRODUCTION: Prophylactic human papillomavirus (HPV) vaccines have been shown to be highly effective in protecting women against cervical infections, high-grade abnormalities and cancer caused by the targeted HPV types. However, the evidence for their effectiveness in women living with HIV (WLWH) is less clear. METHODS: WLWH and HIV-negative women who likely did (birth cohorts 1996 and later) and WLWH and HIV(−) negative who likely did not (birth cohorts before 1996) receive HPV vaccination (n=3028; 757 participants for each of the four groups). Between groups, we will compare cervicovaginal, anal and oral prevalent and 6–12 month persistent HPV6/11/16/18 infections as measured using a modified AmpFire HPV genotyping assay that tests for 15 high-risk or intermediate-risk HPV genotypes, HPV6 and HPV11. We will also compare the HPV immune response in HPV-vaccinated WLWH to HPV-vaccinated HIV-negative women using an anti-HPV16 and anti-HPV18 ELISA. Vaccination status will be confirmed through national vaccination records. ANALYSIS: We will calculate point prevalence and prevalence of 6–12 month persisting infections by individual HPV-type specific infections and groups of infections for each anatomic site and for each group of women. Results will be stratified by age at vaccination, age at enrolment and the number of doses (3 vs 2) as well as other factors possibly associated with HPV prevalence. Differences in endpoints between groups, overall and between subgroups, will be tested for statistical significance (p<0.05) using Fisher’s exact or Pearson χ(2) test. Differences in geometric mean titres and seropositivity will be tested for statistical significance using the Mann-Whitney and Fisher’s exact tests, respectively. ETHICS AND DISSEMINATION: The study was approved by the Albert Einstein College of Medicine Institutional Review Board and the Rwanda National Ethics Committee. Results will be disseminated through publication in peer-reviewed journals. |
format | Online Article Text |
id | pubmed-9422845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-94228452022-09-12 Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol Murenzi, Gad Shumbusho, Fabienne Hansen, Natasha Munyaneza, Athanase Gage, Julia C Muhoza, Benjamin Kanyabwisha, Faustin Pierz, Amanda Tuyisenge, Patrick Anastos, Kathryn Castle, Philip E BMJ Open Global Health INTRODUCTION: Prophylactic human papillomavirus (HPV) vaccines have been shown to be highly effective in protecting women against cervical infections, high-grade abnormalities and cancer caused by the targeted HPV types. However, the evidence for their effectiveness in women living with HIV (WLWH) is less clear. METHODS: WLWH and HIV-negative women who likely did (birth cohorts 1996 and later) and WLWH and HIV(−) negative who likely did not (birth cohorts before 1996) receive HPV vaccination (n=3028; 757 participants for each of the four groups). Between groups, we will compare cervicovaginal, anal and oral prevalent and 6–12 month persistent HPV6/11/16/18 infections as measured using a modified AmpFire HPV genotyping assay that tests for 15 high-risk or intermediate-risk HPV genotypes, HPV6 and HPV11. We will also compare the HPV immune response in HPV-vaccinated WLWH to HPV-vaccinated HIV-negative women using an anti-HPV16 and anti-HPV18 ELISA. Vaccination status will be confirmed through national vaccination records. ANALYSIS: We will calculate point prevalence and prevalence of 6–12 month persisting infections by individual HPV-type specific infections and groups of infections for each anatomic site and for each group of women. Results will be stratified by age at vaccination, age at enrolment and the number of doses (3 vs 2) as well as other factors possibly associated with HPV prevalence. Differences in endpoints between groups, overall and between subgroups, will be tested for statistical significance (p<0.05) using Fisher’s exact or Pearson χ(2) test. Differences in geometric mean titres and seropositivity will be tested for statistical significance using the Mann-Whitney and Fisher’s exact tests, respectively. ETHICS AND DISSEMINATION: The study was approved by the Albert Einstein College of Medicine Institutional Review Board and the Rwanda National Ethics Committee. Results will be disseminated through publication in peer-reviewed journals. BMJ Publishing Group 2022-08-25 /pmc/articles/PMC9422845/ /pubmed/36008069 http://dx.doi.org/10.1136/bmjopen-2022-061650 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Global Health Murenzi, Gad Shumbusho, Fabienne Hansen, Natasha Munyaneza, Athanase Gage, Julia C Muhoza, Benjamin Kanyabwisha, Faustin Pierz, Amanda Tuyisenge, Patrick Anastos, Kathryn Castle, Philip E Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol |
title | Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol |
title_full | Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol |
title_fullStr | Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol |
title_full_unstemmed | Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol |
title_short | Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol |
title_sort | long-term human papillomavirus vaccination effectiveness and immunity in rwandan women living with and without hiv: a study protocol |
topic | Global Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422845/ https://www.ncbi.nlm.nih.gov/pubmed/36008069 http://dx.doi.org/10.1136/bmjopen-2022-061650 |
work_keys_str_mv | AT murenzigad longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT shumbushofabienne longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT hansennatasha longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT munyanezaathanase longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT gagejuliac longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT muhozabenjamin longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT kanyabwishafaustin longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT pierzamanda longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT tuyisengepatrick longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT anastoskathryn longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol AT castlephilipe longtermhumanpapillomavirusvaccinationeffectivenessandimmunityinrwandanwomenlivingwithandwithouthivastudyprotocol |